Salicylic Acid → (R)-methyl 2-(2-hydroxybenzamido)-3-mercaptopropanoate
反応式
[C:1]([OH:10])(=O)[C:2]1[C:3](=[CH:5][CH:6]=[CH:7][CH:8]=1)[OH:4].Cl.[CH3:12][O:13][C:14](=[O:19])[C@H:15]([CH2:17][SH:18])[NH2:16].CCN=C=NCCCN(C)C.CN1CCOCC1>CC#N.CCOC(C)=O>[OH:4][C:3]1[CH:5]=[CH:6][CH:7]=[CH:8][C:2]=1[C:1]([NH:16][C@@H:15]([CH2:17][SH:18])[C:14]([O:13][CH3:12])=[O:19])=[O:10]参加物
実験手順
Separately, salicylic acid (152 mg, 1.10 mmol) was taken up in CH3CN (10 mL) along with L-cysteine methyl ester hydrochloride (189 mg, 1.10 mmol), EDCI (350 mg) and N-methylmorpholine (120 μL). The reaction mixture was stirred at room temperature for 3 h. It was then diluted with EtOAc. The organic layer was washed with saturated aqueous NaHCO3 and brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to afford crude (R)-methyl 2-(2-hydroxybenzamido)-3-mercaptopropanoate. This material was then taken up in CH3CN (3 mL) along with (4Z,7Z,10Z,13Z,16Z,19Z)—N-(2-(2,5-dioxo-2H-pyrrol-1(5H)-yl)ethyl)docosa-4,7,10,13,16,19-hexaenamide (315 mg, 0.7 mmol) and stirred at room temperature for 30 minutes. The reaction mixture was then concentrated under reduced pressure. Purification by silica gel chromatography (CH2Cl2) afforded (R)-methyl 3-(1-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2,5-dioxopyrrolidin-3-ylthio)-2-(2-hydroxybenzamido)propanoate (140 mg). Mass calculated for C39H51N3O7S: 705.34; found: [M+H]+=706.
後処理
- washThe organic layer was washed with saturated aqueous NaHCO3 and brine
- dry with materialThe organic layer was dried over Na2SO4
- concentrationconcentrated under reduced pressure
出典と根拠
- ORDレコード
- ord-f050b6c21cf142d6a755dc86bdb2d6d3
- 出典データセット
- uspto-grants-2014_09
- 特許番号
- US08846972B2
反応ノート
読み込み中…